Nuvalent (NUVL) | Stock Overview & Key Data
Nuvalent Performance Comparison
Stock Range
Today's Range
Low: $73.68
High: $76.44
on August 22, 2025
52 Week Range
Low: $55.53
High: $113.51
on April 9, 2025
on September 16, 2024
All-Time High: $113.51 on September 16, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$5.3B
EPS
-4.92
P/E Ratio (TTM)
-19.36
Forward P/E
-17.37
P/B Ratio
5.64
PEG Ratio
-0.33
Div. Yield
N/A
ROE
-43.55%
Beta
1.301
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-26.37%
Return on Equity (TTM)
-43.55%
EBITDA
$0
Net Income (TTM)
$-343.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Nuvalent NUVL | 5.31B Mid-cap | 0.05% | -5.70% | 3.89% | -2.50% | -4.89% | -10.83% | 383.35% | 316.88% |
| Vertex VRTX | 100.19B Large-cap | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 62.88B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.58B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.99% | 368.51% | 65.93% |
| Madrigal MDGL | 9.07B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
2.83%
Institutional Ownership
109.13%
Shares Short
5M
Short Ratio
10.75
Short % of Shares Outstanding
17.29%
Average 10-Day Volume
440K
Average 90-Day Volume
477K
Nuvalent Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Nuvalent would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NUVL's 52-week high and low?
- In the last 52 weeks, Nuvalent reached a high of $113.51 (on September 16, 2024) and a low of $55.53 (on April 9, 2025).
- What is the market cap and P/E ratio for NUVL?
- Curious about Nuvalent's size and valuation? Its market capitalization stands at 5.31B. When it comes to valuation, the P/E ratio (trailing twelve months) is -19.36, and the forward P/E (looking ahead) is -17.37.
- Does NUVL pay dividends? If so, what's the yield?
- As for dividends, Nuvalent isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Nuvalent's main competitors or similar companies to consider before investing?
When looking at Nuvalent, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN62.88B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.58B Healthcare Biotechnology 93.99% 368.51% Madrigal
MDGL9.07B Healthcare Biotechnology 64.07% 491.89% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Nuvalent Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Nuvalent's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -43.55%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for NUVL?
- Looking at Nuvalent's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of NUVL stock is held by insiders and institutions?
- Wondering who owns Nuvalent stock? Company insiders (like executives and directors) hold about 2.83% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.13%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.